期刊文献+

罗格列酮治疗2型糖尿病伴原发性高血压疗效观察 被引量:10

在线阅读 下载PDF
导出
摘要 目的:观察罗格列酮治疗2型糖尿病伴原发性高血压的临床疗效。方法:将80例2型糖尿病伴原发性高血压患者随机均分为对照组和治疗组,对照组给予二甲双胍、贝那普利、阿司匹林治疗,治疗组在对照组治疗基础上口服罗格列酮,疗程均为3个月。观察2组患者治疗前后血压、空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、空腹血浆胰岛素(FINS)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)的变化。结果:治疗后2组收缩压、舒张压、FPG2、hPG、HbA1c、FINS、TG差异均有统计学意义(P<0.01)。结论:罗格列酮在与二甲双胍产生协同作用明显降低血糖水平、改善胰岛素抵抗的同时,还可以降低患者血压,从而使2型糖尿病合并高血压患者的血糖和血压同时得到更好的控制。
作者 武文
出处 《蚌埠医学院学报》 CAS 2011年第9期994-996,共3页 Journal of Bengbu Medical College
  • 相关文献

参考文献8

  • 1Sutton SJM,Rendell M,Pandona P,et al.A comParison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes[J].Diabetes Care,2002,25(11):2058-2064.
  • 2Winlson PW.Diabetes mellitus and coronary heart disease[J].Am J Kidney Dis,1998,32(1):89-100.
  • 3陈新谦,金有豫,汤光.新编药物学[M].15版.北京:人民卫生出版社,2006.311-508.
  • 4Kawano Y,Okuda N,Minami J,et al.Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients[J].J Hypertens,2000,18(10):1451-1455.
  • 5李光伟,王金平,李春梅,陈燕燕,杨文英,邢小燕,刘克莉,唐玉龙,黎辉.胰岛素增敏剂罗格列酮抗高血压作用探讨[J].中华内科杂志,2004,43(12):907-910. 被引量:55
  • 6孔俭,孙捷,马丽,汲宏磊.罗格列酮的降压作用及降压机理的研究[J].中国老年学杂志,2003,23(9):565-566. 被引量:18
  • 7孙雅逊,胡申江.列酮类药物与高血压[J].国际心血管病杂志,2006,33(2):86-89. 被引量:9
  • 8Subodh V.Direct vasodepressor effects of pioglitazone in spontaneously hypertensiverats[J].Pharmacology,1998,56(17):7-16.

二级参考文献42

  • 1[1]Kemnitz JW,Elson DF.Roecker EB,et al.Pioglitazone increases insulin sensitivity,reduces blood glucose,insulin,and lipid levels,and lowers blood pressure,in obese,insulin-resistant rhesus monkeys[J].Diabetes,1994,43 (2):204-211.
  • 2[2]Ogihara T,Rakugi H,Ikegami H,et al.Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives[J].Am J Hypertens,1995,8(3):316-320.
  • 3[3]Yoshioka S,Nishino H,Shiraki T,et al.Antihypertensive effects of CS-045 treatment in obese Zucker rats[J].Metabolism,1993,42 (1):75-80.
  • 4[4]Yoshimoto T,Naruse M,Nishikawa M,et al.Antihypertensive and vasculo-and renoprotective effects of pioglitazone in genetically obese diabetic rats[J].Am J Physiol,1997,272(6 Pt 1):E989-E996.
  • 5[5]Buchanan TA,Meehan WP,Jeng YY,et al.Blood pressure lowering by pioglitazone.Evidence for a direct vascular effect[J].J Clin Invest,1995,96(1):354-360.
  • 6[6]Nolan JJ,Ludvik B,Beerdsen P,et al.Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone[J].N Engl J Med,1994,331 (18):1188-1193.
  • 7[7]Ledingham JM,Laverty R.Effects of glitazones on blood pressure and vascular structure in mesenteric resistance ar teries and basilar artery from genetically hypertensive rats[J].Clin Exp Pharmacol Physiol,2005,32(11):919,925.
  • 8[8]Barroso I,Gurnell M,Crowley VE,et al.Dominant negative mutations in human PPARgamma associated with severe insulin resistance,diabetes mellitus and hypertension[J].Nature,1999,402(6764):880-883.
  • 9[9]Savage DB,Tan GD,Acerini CL,et al.Human metabolic syndrome resulting from dominant negative mutations in the nuclear receptor peroxisome proliferator-activated receptor gamma[J].Diabetes,2003,52(4):910-917.
  • 10[10]Walker AB,Chattington PD,Buckingham RE,et al.The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats[J].Diabetes,1999,48(7):1448-1453.

共引文献86

同被引文献101

引证文献10

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部